Evaluating the effectiveness of PD-1 antibody therapy in cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the efficacy and safety of PD(L)-1 antibody therapy for malignant tumors using real-world data. It will analyze treatment outcomes based on RECIST V1.1 and iRECIST criteria, while safety will be evaluated according to CTCAE V5.0 standards. The study plans to enroll 3000 adult cancer patients treated at the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, utilizing previous immune function monitoring results alongside clinical case data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years.
2. Pathologically confirmed malignant tumors.
3. Complete medical records.
4. Assessable immune function test data.

Exclusion Criteria:

1. Age \<18 years.
2. No confirmed tumor pathology.
3. Untraceable medical records.
4. Non-assessable immune function tests.

Where it's running

• Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
  Zhengzhou, Henan, China Recruiting

Study contacts

• Study coordinator: Xiaomin Fu
• Email: fuxiaomin0880@126.com
• Phone: +86037165587483

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mycophenolate mofetil with prednisone for immune-related hepatitis from cancer therapy

  This study tests whether starting mycophenolate mofetil plus prednisone can help liver inflammation caused by immune checkpoint inhibitors in adults with moderate to severe immune-related hepatitis.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07663422

• Thymosin Alpha-1 plus PD-1 therapy in older adults with advanced melanoma

  This trial tests whether adding Thymosin Alpha-1 to a PD-1 antibody helps people age 60 and up with advanced melanoma.

  Recruiting at 2 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07644897

• Inhaled budesonide to prevent recurrent checkpoint inhibitor–related pneumonitis

  This study tests whether adding inhaled budesonide to usual care can prevent recurrence of pneumonitis in adults who developed grade 2 or higher lung inflammation from checkpoint inhibitor immunotherapy.

  Recruiting Phase 2 AHS Cancer Control Alberta · Calgary, Alberta · NCT06860542

• Investigating serum ferritin as a biomarker for immune-related adverse events

  This study is testing if a blood marker called serum ferritin can help doctors identify and predict immune-related side effects in patients with cancer receiving different types of treatment.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06702566

• Exploring PD-1 therapy duration for rectal cancer treatment

  This study is testing how long PD-1 therapy should be given to people with stage II-III rectal cancer to see if it helps them have the best chance of a complete response before surgery.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT06613165

• Vedolizumab to prevent ICI-related diarrhea or colitis in cancer patients

  This study tests whether vedolizumab can prevent immune checkpoint inhibitor–related diarrhea or colitis in adults with unresectable or metastatic melanoma, lung, or kidney cancer starting immunotherapy.

  Recruiting Phase 2/3 AHS Cancer Control Alberta · Calgary, Alberta and 1 other locations · NCT06337695

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.